Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia

American Journal of Cardiology

Volumn 86, Issue 7, 2000, Pages 759-763

  Ballantyne, Christie M ^a   McKenney, James ^b   Trippe, Bruce S ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b National Clinical Research Inc   (United States)

^c Drug Res and Analysis Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TABLET;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CAPSULES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; MIDDLE AGED; TABLETS; TRIGLYCERIDES;

EID: 0034307105     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01076-6     Document Type: Article

References (8)

1. Smith H.T., Jokubaitis L.A., Troendle A.J. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens. 6:1993;375S-382S.
2. Tse F.L.S., Jaffe J.M., Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol. 32:1992;630-638.
3. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Downton M., Franklin F.A., Gould A.L., Hesney M., Higgins J., Hurley D.P., Langendorfer A., Nash D.T., Pool J.L., Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results I . Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 151:1991;43-49.
4. Christians U., Jacobsen W., Floren L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients are statins mechanistically similar? Pharmacol Ther. 80:1998;1-34.
5. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
6. Langtry H.D., Markham A. Fluvastatin a review of its use in lipid disorders . Drugs. 57:1999;583-606.
7. Serruys P.W., Foley D.P., Jackson G., Bonnier H., Macaya C., Vrolix M., Branzi A., Shepherd J., Suryapranata D., de Feyter P.J., Melkert R., van Es G.A., Pfister P.J. A randomized placebo-controlled trial of fluvastatin for the prevention of restenosis after successful coronary balloon angioplasty results of the Fluvastatin Angioplasty Restenosis (FLARE) trial . Eur Heart J. 20:1999;58-69.
8. Schuster H., Berger J., Luft F.C. Randomised, double-blind, parallel-group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia. Br J Cardiol. 5:1998;597-602.